Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

This study provides the first data about castration-resistant prostate cancer (CRPC) treatments in patients treated upfront with (androgen deprivation therapy) ADT+docetaxel for metastatic prostate cancer to our knowledge. Most men treated upfront with ADT and docetaxel for metastatic castration-naive prostate cancer who subsequently developed metastatic CRPC received at least one treatment for metastatic CRPC, with no unexpected pattern of toxicity. Rechallenging docetaxel at castration-resistance had limited activity in patients with metastatic prostate cancer treated upfront with ADT+docetaxel. Available data on abiraterone and enzalutamide support maintained efficacy in this setting.